Tag
NYSEARCA: XBI
- Allarity Therapeutics settles US$4.9M liability for US$1M
- Rezolute reports 13 responders in preliminary Phase 3 tumor study
- DiaMedica Therapeutics reaches 200 patients in pivotal stroke trial
- Arbutus Biopharma says FDA lifts AB‑101 clinical hold
- BioCryst Pharmaceuticals wins FDA approval for 150 mg ORLADEYO pellets
- Disc Medicine reports bitopertin Phase 3 success in EPP
- Vir Biotechnology signs Gilead cancer deal with US$90M upfront
- Mayne Pharma wins dismissal of Cosette appeal over abandoned takeover
- Genmab A/S reports 45.9% Rina‑S response in ovarian cancer trial
- Nanexa AB shares jump 105% on Novo Nordisk drug-delivery licence
- aTyr Pharma says FDA aligned on 372‑patient sarcoidosis trial
- Mesoblast gets FDA approval for new Ryoncil potency assay
- Amgen says dazodalibep met Phase 3 Sjögren's endpoint